All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Boris Sepesi, MD
Ian Bostock, MD, MS

Presentations

1. The New IASLC TNM Pleural Mesothelioma Staging and Its Effect on Treatment Options
   Valerie Rusch, MD
    
2. The Role of Pleurectomy and Decortication in Pleural Mesothelioma: How I Do It
   Andrea Wolf, MD, MPH
    
3. Novel Perioperative Analgesia Modalities During Pleurectomy and Decortication for Pleural Mesothelioma
   Jeffrey B. Velotta, MD, FACS
   Disclosure(s): Asparaglue: Consultant (Ongoing)
    
4. Panel Discussion
    
5. Updated Post-Recurrence Survival Outcomes in Patients Undergoing Pleurectomy/Decortication for Pleural Mesothelioma
   Akifumi Nakamura, PhD, MD
    
6. Prolonged Survival is Possible in Mesothelioma Patients Managed Non-Operatively: A National Cancer Database Analysis
   Peter L. Zhan, MD
    
7. Neoadjuvant Immunotherapy in the Treatment of Pleural Mesothelioma
   Bryan M. Burt, MD
   Disclosure(s): Bayou Surgical, Inc: Owner/Co-Owner Founder/Co-Founder (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), This is a startup company that I founded which is commercializing a device for minimally invasive surgery (Ongoing)
    
8. Adjuvant Systemic and Immunotherapy Options in the Treatment of Pleural Mesothelioma
   Jennifer Marie Suga, MD, MPH
   Disclosure(s): Astrazeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Strata Oncology: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
    
9. Panel Discussion